<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117141</url>
  </required_header>
  <id_info>
    <org_study_id>ELN-0302002</org_study_id>
    <nct_id>NCT02117141</nct_id>
  </id_info>
  <brief_title>To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules</brief_title>
  <official_title>A Pilot Study in Healthy Volunteers to Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules, in Both Fed and Fasted States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in
           both fed and fasted states

        -  Evaluate the safety and tolerability of the test compound administered orally
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety parameters assessed included medical history, physical examination, vital signs,
      12-lead ECGs, clinical laboratory testing and adverse event assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in both fed and fast states</measure>
    <time_frame>Day 1-2</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HC-ER 20 mg capsule (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of a HC-ER 20 mg capsule (fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC-ER 20 mg capsule (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of HC-ER 20mg capsule (fed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-ER 20 mg capsule (fasted)</intervention_name>
    <description>Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)</description>
    <arm_group_label>HC-ER 20 mg capsule (fasted)</arm_group_label>
    <other_name>Zohydro ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-ER 20 mg capsule (fed)</intervention_name>
    <description>Single oral dose HC-ER 20 mg capsule after high fat meal (fed)</description>
    <arm_group_label>HC-ER 20 mg capsule (fed)</arm_group_label>
    <other_name>Zohydro ER</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers.

          -  Aged greater than 18 and less than 45 years.

          -  Were medically healthy with no clinically significant abnormality on the basis of
             medical history, physical examination and laboratory evaluations

          -  Volunteer consented to participate in the study.

          -  Female volunteers were included if they were surgically sterile, or using an
             acceptable method of birth control defined as either oral, injectable, implantable,
             or barrier methods of contraception (ie, diaphragm with spermicidal cream,
             intrauterine device (IUD) with spermicidal cream or condom with spermicidal cream).

        Exclusion Criteria:

          -  Participants were in a clinical trial within the previous 90 days or participants in
             a narcotic analgesic study within the previous 12 months.

          -  Deviation in excess of 10% from the ideal body weight for height according to the
             Metropolitan Life Insurance Tables (1983 edition).

          -  History of drug or alcohol abuse at any time in the past

          -  History of hypersensitivity to the study drug or similar compounds or to
             acetaminophen.

          -  Therapeutic use (for any reason) of narcotic analgesics within the previous year.

          -  Subjects who used tricyclic antidepressants or monoamine oxidase inhibitors at any
             time in the past.

          -  Subjects with a history of, or clinical signs suggestive of, chronic obstructive
             airways disease.

          -  Receipt of any prescription medication (except birth control) within 2 weeks prior to
             entry into the study or receipt of non-prescription or over-the-counter medication
             within one week of study commencement. (Vitamin supplements were acceptable).

          -  Blood donation within the 90 days previous to study entry.

          -  Female volunteers with a positive serum pregnancy test, or at risk of becoming
             pregnant during the study.

          -  Volunteers with a history of smoking (must not have smoked within the last 6 months).

          -  Volunteers with any clinical/biochemical impairment of liver function, or receipt of
             known hepatic enzyme inducing or inhibiting agents within 30 days prior to entry into
             the study.

          -  History or presence of significant hepatic, renal, endocrine, cardiac, nervous,
             gastrointestinal, pulmonary or metabolic disorders.

          -  Any condition or history that the investigator considered might increase the risk to
             the volunteer or interfere with the evaluation of data.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Johnston Stewart, MB, MRCGP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zogenix, Inc.</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food Effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
